Evoke Pharma (EVOK) EBIAT (2020 - 2025)
Historic EBIAT for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.
- Evoke Pharma's EBIAT rose 1190.06% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1497.85%. This contributed to the annual value of -$5.4 million for FY2024, which is 3131.43% up from last year.
- Evoke Pharma's EBIAT amounted to -$1.2 million in Q3 2025, which was up 1190.06% from -$1.6 million recorded in Q2 2025.
- Over the past 5 years, Evoke Pharma's EBIAT peaked at -$1.2 million during Q3 2025, and registered a low of -$2.6 million during Q1 2021.
- Over the past 5 years, Evoke Pharma's median EBIAT value was -$1.8 million (recorded in 2022), while the average stood at -$1.8 million.
- Per our database at Business Quant, Evoke Pharma's EBIAT skyrocketed by 6712.34% in 2021 and then tumbled by 2397.05% in 2025.
- Evoke Pharma's EBIAT (Quarter) stood at -$1.7 million in 2021, then fell by 7.82% to -$1.8 million in 2022, then dropped by 10.21% to -$2.0 million in 2023, then skyrocketed by 39.98% to -$1.2 million in 2024, then increased by 3.06% to -$1.2 million in 2025.
- Its last three reported values are -$1.2 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.3 million during Q1 2025.